We think its portfolio and pipeline support a wide moat, and with the HCV market stabilizing, Gilead needs strong continued innovation in HIV, solid oncology pipeline data, and smart future ...

NPPA fixes retail price of 42 formulations, revise prices based on review orders: Our Bureau, New Delhi Tuesday, February 11, 2025, 13:30 Hrs [IST] The National Pharmaceutical Pri ...